Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gary Albert, Iksung Cho, +26

New England Journal of Medicine

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

Neil Formica, Raburn M. Mallory, Gary Albert, +6

PLoS Medicine

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children

Terry Nolan, Peter Richmond, Neil Formica, +10

Vaccine

VaccinationCross-protectionVaccine DevelopmentVaccine TargetImmunology +6

Population Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in Men, Women, and Children in Australia

Anthony T. Newall, Julia Brotherton, Helen Quinn, +8

Clinical Infectious Diseases

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults

Terry Nolan, Peter Richmond, Maryanne Skeljo, +9

Vaccine

VaccinationVaccine SafetyCross-protectionVaccine DevelopmentImmunology +6

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Raburn M. Mallory, Neil Formica, Susan Pfeiffer, +39

The Lancet Infectious Diseases

VaccinationVaccine SafetyVaccine DevelopmentImmunologyVaccine Testing +5

The impact of diagnosis by legionella urinary antigen test on the epidemiology and outcomes of Legionnaires' disease

Neil Formica, Maria T Yates, Mary Beers, +4

Epidemiology and Infection

Community-acquired PneumoniaMinimal Clinical HeterogeneityMedicineHealthcare-associated InfectionClinical Epidemiology +10

Abattoir‐associated Q fever: a Q fever outbreak during a Q fever vaccination program

Nicole Gilroy, Neil Formica, Mary Beers, +3

Australian and New Zealand Journal of Public Health

VaccinationQ Fever OutbreakQ FeverDisease OutbreakInfection Control +3

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gregory M. Glenn, Gary Albert, +26

ImmunologyImmunodominanceImmunotherapeuticsCovid-19Cross-protection +18

Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine

H. Keipp Talbot, Wendy A. Keitel, Thomas R. Cate, +13

Vaccine

VaccinationVaccine SafetyCross-protectionVaccine DevelopmentImmunology +4